Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $423.00
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $420.00 to $423.00 in a research note published on Tuesday, MarketBeat reports. They currently have a sector perform rating on the pharmaceutical company’s stock. Several other equities research analysts have also recently commented on the company. JPMorgan Chase […]
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price target upped by Royal Bank of Canada from $420.00 to $423.00 in a research note published on Tuesday, MarketBeat reports. They currently have a sector perform rating on the pharmaceutical company’s stock. Several other equities research analysts have also recently commented on the company. JPMorgan Chase […]
